Quest Diagnostics 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jim Davis

최고 경영자

US$12.7m

총 보상

CEO 급여 비율	9.3%
CEO 임기	2yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jim Davis 의 보수는 Quest Diagnostics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$838m
Jun 30 2024	n/a	n/a	US$836m
Mar 31 2024	n/a	n/a	US$842m
Dec 31 2023	US$13m	US$1m	US$850m
Sep 30 2023	n/a	n/a	US$759m
Jun 30 2023	n/a	n/a	US$790m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$12m	US$806k	US$942m
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$4m	US$625k	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$2b
Dec 31 2020	US$4m	US$577k	US$1b
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	US$749m
Mar 31 2020	n/a	n/a	US$771m
Dec 31 2019	US$3m	US$590k	US$835m
Sep 30 2019	n/a	n/a	US$709m
Jun 30 2019	n/a	n/a	US$707m
Mar 31 2019	n/a	n/a	US$720m
Dec 31 2018	US$3m	US$590k	US$733m
Sep 30 2018	n/a	n/a	US$860m
Jun 30 2018	n/a	n/a	US$808m
Mar 31 2018	n/a	n/a	US$782m
Dec 31 2017	US$3m	US$590k	US$769m

보상 대 시장: Jim 의 총 보상 ($USD 12.67M )은 BR 시장( $USD 5.71M ).

보상과 수익: Jim 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jim Davis (61 yo)

2yrs

테뉴어

US$12,673,834

보상

Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Davis	Chairman	2yrs	US$12.67m	0.067% R$ 69.7m
Sam Samad	Executive VP & CFO	2.3yrs	US$3.98m	0.016% R$ 16.3m
Michael Prevoznik	Senior VP & General Counsel	25.3yrs	US$2.25m	0.039% R$ 41.0m
Catherine Doherty	Executive Vice President of Regional Businesses	no data	US$3.16m	0.058% R$ 60.3m
Karthik Kuppusamy	Senior Vice President of Clinical Solutions	2.3yrs	US$2.02m	0.010% R$ 10.9m
Michael Deppe	Senior VP	5.6yrs	데이터 없음	0.032% R$ 33.2m
Murali Balakumar	Senior VP	less than a year	데이터 없음	데이터 없음
Shawn Bevec	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Kristin Wallace	Senior VP & Chief Compliance Officer	2.1yrs	데이터 없음	데이터 없음
Gary Samuels	Senior VP & Chief Communications Officer	28yrs	데이터 없음	데이터 없음
Cecilia McKenney	Senior VP & Chief Human Resources Officer	6.8yrs	데이터 없음	데이터 없음
Dermot Shorten	Senior Vice President of Strategy	8.8yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: Q1UE34 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Davis	Chairman	2yrs	US$12.67m	0.067% R$ 69.7m
Timothy Main	Independent Director	10.8yrs	US$315.44k	0.022% R$ 23.4m
Robert Carter	Director	less than a year	데이터 없음	데이터 없음
Timothy Ring	Lead Independent Director	12.9yrs	US$345.94k	데이터 없음
Gary Pfeiffer	Independent Director	19.9yrs	US$342.12k	데이터 없음
Denise Morrison	Independent Director	5.8yrs	US$312.33k	0.0026% R$ 2.7m
Vicky Gregg	Independent Director	10.3yrs	US$315.73k	0.016% R$ 16.8m
Wright Lassiter	Independent Director	4.7yrs	US$300.44k	데이터 없음
Tracey Doi	Independent Director	3.3yrs	US$300.44k	데이터 없음
Luiz Diaz	Independent Director	1.5yrs	US$280.41k	데이터 없음

5.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: Q1UE34 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

Quest Diagnostics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Quest Diagnostics Elects Robert B. Carte to Board of Directors

Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Announces Jim Davis Joins Board of Directors

Recent updates

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 29, 2025

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select Assets of Outreach Laboratory Services Business of University Hospitals from University Hospitals Health System, Inc.

Quest Diagnostics Incorporated to Report Q3, 2024 Results on Oct 22, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select laboratory assets of Allina Health System, Inc.

Quest Diagnostics Incorporated Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated to Report Q2, 2024 Results on Jul 23, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of PathAI Diagnostics.

Quest Diagnostics Elects Robert B. Carte to Board of Directors

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on July 22, 2024

Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Quest Diagnostics Incorporated to Report Q1, 2024 Results on Apr 23, 2024

Quest Diagnostics Incorporated Announces the Launch of MelaNodal Predict

Quest Diagnostics Incorporated Announces the Availability of the First Consumer-Initiated, Physician-Ordered Blood-Draw Test for PFAS Chemicals

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated to Report Q4, 2023 Results on Feb 01, 2024

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 31, 2024

Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year 2023

Quest Diagnostics Incorporated to Report Q3, 2023 Results on Oct 24, 2023

Quest Diagnostics Grants Fda Breakthrough Designation for Its Adeno-Associated Virus Test

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on October 23, 2023

QuQuest Diagnostics Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com

Quest Diagnostics Incorporated Revises Earnings Guidance for the Full Year 2023

Quest Diagnostics Announces the Launch of its First Consumer-Initiated Genetic Test

Quest Diagnostics Incorporated to Report Q2, 2023 Results on Jul 26, 2023

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 25, 2023

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select Assets of the Laboratory Services Business from The New York and Presbyterian Hospital.

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2023

Quest Diagnostics Incorporated to Report Q4, 2022 Results on Feb 02, 2023

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of Summa Health System, Inc.

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on February 1, 2023

Quest Diagnostics Announces Jim Davis Joins Board of Directors

Quest Diagnostics Incorporated Announces Executive Changes

Quest Diagnostics Incorporated Announces Management Changes

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select assets of Summa Health System, Inc.

Quest Diagnostics Incorporated to Report Q3, 2022 Results on Oct 20, 2022

FDA Authorizes Quest Diagnostics' Proprietary Monkeypox Test for Emergency Use

Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel That Includes Hepatitis C Screening

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on October 19, 2022

Quest Diagnostics Incorporated Revises Consolidated Earnings Guidance for the Full Year of 2022

Quest Diagnostics Launches Monkeypox Virus Testing

Quest Diagnostics Incorporated to Report Q2, 2022 Results on Jul 21, 2022

New Quest Diagnostics Health Trends Study, in Collaboration with Cdc, Shows Less Than Half of Pregnant People Screened for Hepatitis C

Quest Diagnostics Incorporated Names Sam Samad as Executive Vice President with Effect from July 11, 2022

Quest Diagnostics Incorporated Announces the resignation of Carrie Eglinton Manner as Senior Vice President, Advanced and General Diagnostics and Clinical Solutions

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 20, 2022

Quest Diagnostics Incorporated Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Quest Diagnostics Incorporated Announces Mark Guinan Will Retire as Chief Financial Officer

Quest Diagnostics Incorporated to Report Q1, 2022 Results on Apr 21, 2022

Quest Diagnostics Incorporated, Annual General Meeting, May 18, 2022

Quest Diagnostics Appoints James E. Davis as its Next Chief Executive Officer, Effective November 1, 2022 Succeeding Steve Rusckowski

Quest Diagnostics Launches Virtual Preventive Care Service Through QuestDirect™ to Help Individuals Take Control of Their Health

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Pack Health, LLC.

Quest Diagnostics Incorporated Provides Preliminary Earnings Guidance for the Fourth Quarter of 2021

Quest Diagnostics Incorporated (NYSE : DGX) acquired Assets of Labtech Diagnostics.

Quest Diagnostics Incorporated Revises Earnings Guidance for the Full Year 2021

Nationwide Laboratory Services, Inc. acquired Assets from Nationwide Laboratory Services, Inc.

Quest Diagnostics Incorporated(NYSE:DGX) dropped from Russell 1000 Dynamic Index

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on July 21, 2021

Quest Diagnostics Incorporated Revises Earnings Guidance for the First Half of 2021